Authors: McLeod, HL Cassidy, J Powrie, RH Priest, DG Zorbas, MA Synold, TW Shibata, S Spicer, D Bissett, D Pithavala, YK Collier, MA Paradiso, LJ Roberts, JD

Citation: Hl. Mcleod et al., Pharmacokinetic and pharmacodynamic evaluation of the glycinamide ribonucleotide formyltransferase inhibitor AG2034, CLIN CANC R, 6(7), 2000, pp. 2677-2684

Authors: Roberts, JD Shibata, S Spicer, DV McLeod, HL Tombes, MB Kyle, B Carroll, M Sheedy, B Collier, MA Pithavala, YK Paradiso, LJ Clendeninn, NJ

Citation: Jd. Roberts et al., Phase I study of AG2034, a targeted GARFT inhibitor, administered once every 3 weeks, CANC CHEMOT, 45(5), 2000, pp. 423-427

Authors: Jackson, KA Rosenbaum, SE Kerr, BM Pithavala, YK Yuen, G Dudley, MN

Citation: Ka. Jackson et al., A population pharmacokinetic analysis of nelfinavir mesylate in human immunodeficiency virus-infected patients enrolled in a phase III clinical trial, ANTIM AG CH, 44(7), 2000, pp. 1832-1837

Authors: Pithavala, YK Heizer, WD Parr, AF O'Connor-Semmes, RL Brouwer, KLR

Citation: Yk. Pithavala et al., Use of the InteliSite (R) capsule to study ranitidine absorption from various sites within the human intestinal tract, PHARM RES, 15(12), 1998, pp. 1869-1875